BackOrion Biotech Opportunities - Warrants (15/04/2025) Overview
Orion Biotech Opportunities Corp - Warrants (15/04/2025)

Orion Biotech Opportunities - Warrants (15/04/2025) Return on Equity

Orion Biotech Opportunities - Warrants (15/04/2025) (ORIAW) has a ROE of 2515104.48%, above the sector sector average of 11.64%.

Get informed when a big investor buys or sells

+ Follow

ROE

2515104.48%

Return on Equity

2515104.48%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

Orion Biotech Opportunities - Warrants (15/04/2025) (ORIAW) FAQ

The latest ROE for ORIAW is 2515104.48%. That is above the sector sector average of 11.64%. Investors often review this figure alongside Orion Biotech Opportunities - Warrants (15/04/2025)'s historical trend and sector peers before judging valuation or financial health.

Against its sector companies, ORIAW currently prints 2515104.48% for ROE, while the sector average sits near 11.64%. That is roughly 21613590.6% above the sector mean. Large gaps often invite a closer look at Orion Biotech Opportunities - Warrants (15/04/2025)'s growth, margins, and balance sheet.

Return on Equity shows how effectively Orion Biotech Opportunities - Warrants (15/04/2025) converts resources into returns. At 2515104.48%, ORIAW may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting ORIAW's ROE (2515104.48%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.